CEO Stanley Erck said the term “reflects the urgent medical need for a more effective vaccine against influenza, especially in older adults, who often have serious and sometimes life-threatening complications.”
The news is a pleasant surprise for the company, which has declined by 90% in the past twelve months, primarily due to the failure of Phase 3 ResVax in early 2019.
By January, the CDC announced that between 9.7 and 14 million people had flu in the United States and that this season is expected to be one of the worst in decades. The high incidence of viral infection is due to the fact that this year’s flu vaccine, according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infection, “doesn’t go very well with a strain called B / Victoria” diseases.
<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "Taking into account the effects of a new flu vaccine are monumental, and this fact has not gone unnoticed by the FBR analyst B. Riley Mayank Mamtani points out that there is additional tailwind that could drive NVAX after 28 days ahead of the upcoming Phase 3 measurement of NanoFlu immunogenicity, fact has not gone unnoticed by the road. B. Riley’s FBR analyst Mayank Mamtani pointed out that there are additional tailwinds that could drive NVAX ahead of the upcoming 28-day measurement of phase 3 NanoFlu immunogenicity.
First of all, the data from phase 2 already showed that the vaccine FluZone, the equivalent product of the current market leader Sanofi, is superior. It should also be noted that a quick, three-week test enrollment period of approximately 2.7 thousand healthy older adults took place in October 2019, and there was an order by the President to update the modern influenza vaccine to public health and national security to improve, both of which are encouraging signs.
However, Mamtani warns investors that a significant improvement in NVAX’s balance sheet may not occur immediately. “We note that the balance sheet surplus is weighing heavily on the stock reaction as a commercial start is planned for the 2021 flu season and the resulting strategic transaction with a large vaccine manufacturer for global marketing may not be immediately after the release of the data,” said he.
Nevertheless, the five-star analyst remains confident that NVAX will be ahead in the long term. “NVAX has agreed an accelerated approval process with the agency after positive results for Ph. III, which our current 35% probability of technical success considers conservative,” he commented.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Based on all the above factors, Mamtani has decided Um stay with the bulls and repeat the buy recommendation and price target of $ 12. If the target is achieved, the stocks could post a profit of 169% within 12 months. Click here) “data-reactid =” 27 “> Based on all of these factors, Mamtani decided to stay with the bulls and repeated his buy rating and price target of $ 12. If the target is met, the stock could reach 169% of the twelve – monthly profit. (To see Mamtani’s track record, Click here)
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "What does the rest of the street think? In terms of activities other analysts have been relatively quiet as only two other analysts have reviewed the health care name in the past three months, although both are optimistic as well, and the average price target of $ 18.83 implies an impressive upside potential of 331%. (See Novavax stock analysis on TipRanks) “data-reactid =” 28 “> What does the rest of the street think? According to the break in consensus, it was relatively quiet when it came to other analyst activities, with only 2 other analysts reviewing the name of the healthcare system in the last quarter. However, the message is clear : NVAX is a strong buy, and the average price target of $ 18.83 implies an impressive upside potential of 331% (see Novavax stock analysis at TipRanks).